Key takeaways
- Algorithmiq is targeting quantum advantage for life science problems like protein interactions and drug discovery using today's noisy gate-based machines, not waiting for fault tolerance
- Their approach combines quantum hardware with classical computation and error mitigation techniques rather than relying on full error correction
- Sabrina predicts a timeline for when quantum advantage in life sciences could actually arrive, tied to near-term NISQ hardware improvements rather than long-term fault-tolerant roadmaps
- The company's path traces back to her academic career in open quantum systems, which shaped the noise-aware, hybrid strategy Algorithmiq now uses commercially
Summary
Sabrina Maniscalco, co-founder and CEO of Algorithmiq, a company that is bringing quantum to life and to life sciences, is interviewed by Yuval Boger. Sabrina and Yuval talk about Algorithmiq’s approach to achieving quantum advantage for life science applications using NISQ-era gate-based machines, her prediction for when quantum advantage will be achieved, the journey from Sicilia to Finland, and much more.
Interested in the transcript? Read it on the Quantum Computing Report site